AoU Research Priorities Use Cases

Community Member

Development of Clinically Relevant Cellular-based microbiosensors and Stable, Robust Genetic Circuits

As cell-based strategies constitute a novel paradigm in microbiome therapeutics, an emerging U24 and U41 framework focused on using natural and recombinant probiotics, their designed microbial consortia and their validated selective antimicrobials. Recent efforts seek to augment the natural benefits of probiotics through recombinant expression of therapeutic biomolecules, which could overcome issues such as bioavailability and drug inactivation associated with oral administration.

Keywords

Voting

0 votes
Ideate
Idea No. 854